Vyome Holdings, Inc. (HIND)
NASDAQ: HIND · Real-Time Price · USD
1.890
0.00 (0.00%)
At close: May 18, 2026, 4:00 PM EDT
1.890
0.00 (0.00%)
After-hours: May 18, 2026, 4:00 PM EDT
Vyome Holdings Revenue
Vyome Holdings had revenue of $31.59K in the quarter ending March 31, 2026, a decrease of -84.09%. This brings the company's revenue in the last twelve months to $152.72K, down -59.66% year-over-year. In the year 2025, Vyome Holdings had annual revenue of $319.71K with 24.43% growth.
Revenue (ttm)
$152.72K
Revenue Growth
-59.66%
P/S Ratio
83.18
Revenue / Employee
$8,485
Employees
18
Market Cap
13.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 319.71K | 62.77K | 24.43% |
| Dec 31, 2024 | 256.94K | -159.00K | -38.23% |
| Dec 31, 2023 | 415.94K | 33.08K | 8.64% |
| Dec 31, 2022 | 382.87K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHIND News
- 6 days ago - Vyome signs exclusive license agreement with Impetis - TheFly
- 6 days ago - Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity - Business Wire
- 14 days ago - Vyome initiated with a Buy at Litchfield Hills - TheFly
- 26 days ago - Vyome Holdings presents Phase 2 study results on VT-1953 - TheFly
- 26 days ago - Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 - Business Wire
- 6 weeks ago - Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026 - TheFly
- 6 weeks ago - Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 - Business Wire
- 7 weeks ago - Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year - TheFly